These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 3045334)
1. Human natural lymphocyte effector cells: definition, analysis of activity, and clinical effectiveness. Ortaldo JR; Longo DL J Natl Cancer Inst; 1988 Sep; 80(13):999-1010. PubMed ID: 3045334 [TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
4. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells. Burns GF; Triglia T; Werkmeister JA J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374 [TBL] [Abstract][Full Text] [Related]
5. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. Phillips JH; Lanier LL J Exp Med; 1986 Sep; 164(3):814-25. PubMed ID: 3489062 [TBL] [Abstract][Full Text] [Related]
6. Human cytotoxic effector cells: definition and analysis of activity. Ortaldo JR Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid: prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity. Bagnasco M; Venuti D; Paolieri F; Torre G; Ferrini S; Canonica GW J Clin Endocrinol Metab; 1989 Oct; 69(4):832-6. PubMed ID: 2789232 [TBL] [Abstract][Full Text] [Related]
8. Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities. Komiyama A; Kawai H; Yabuhara A; Yanagisawa M; Miyagawa Y; Ota M; Hasekura H; Akabane T Pediatrics; 1990 Mar; 85(3):323-30. PubMed ID: 2304785 [TBL] [Abstract][Full Text] [Related]
9. [Identification and characterization of effector lymphocytes lysing autologous tumor cells]. Kumagai K; Fujii M; Abo T; Sawada H; Kato M; Itoh K; Satoh T Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1462-8. PubMed ID: 2658829 [TBL] [Abstract][Full Text] [Related]
10. Human tumor-infiltrating lymphocytes: a marker of host response. Vose BM; Moore M Semin Hematol; 1985 Jan; 22(1):27-40. PubMed ID: 3155876 [TBL] [Abstract][Full Text] [Related]
11. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells. Atzpodien J; Gulati SC Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310 [TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer cells. Analysis of progenitors and effectors. Ortaldo JR; Mason A; Overton R J Exp Med; 1986 Oct; 164(4):1193-205. PubMed ID: 3093626 [TBL] [Abstract][Full Text] [Related]
13. Expression of B7-1 by Pam 212 squamous cell carcinoma enhances tumor cell interactions with dendritic epidermal cells but does not affect in vivo tumor growth. Yeh KY; Chen Z; Nasir A; Ohsuga Y; Takashima A; Lord EM; Gaspari AA J Invest Dermatol; 1997 Dec; 109(6):728-33. PubMed ID: 9406812 [TBL] [Abstract][Full Text] [Related]
14. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
15. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
16. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Owen-Schaub LB; Gutterman JU; Grimm EA Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408 [TBL] [Abstract][Full Text] [Related]
17. Differentiation of NK-like cells from OKT3-, OKT11+, and OKM1+ small resting lymphocytes by culture with autologous T cell blasts and lymphokine. Warren HS J Immunol; 1984 Jun; 132(6):2888-94. PubMed ID: 6233364 [TBL] [Abstract][Full Text] [Related]
18. Cytolytic effector cells against human tumors: distinguishing phenotype and function. Stötter H; Lotze MT Cancer Cells; 1990 Feb; 2(2):44-6, 51-5. PubMed ID: 2204383 [TBL] [Abstract][Full Text] [Related]
19. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment. Lotzová E Nat Immun Cell Growth Regul; 1990; 9(4):253-64. PubMed ID: 2215514 [TBL] [Abstract][Full Text] [Related]
20. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. Tilden AB; Itoh K; Balch CM J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]